Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.
Resumen:
Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT.
| 2026 | |
|
Agencia Nacional de Investigación e Innovación Brain vascular malformation Consorsium National Institute of Health |
|
|
vascular pathology BMP9-ALK1-SMAD signaling endothelial cell Hereditary Hemorrhagic Telangiectasia arteriovenous malformation Ciencias Médicas y de la Salud Medicina Clínica Sistemas Cardíaco y Cardiovascular |
|
| Inglés | |
| Institut Pasteur de Montevideo | |
| IPMON en REDI | |
| https://hdl.handle.net/20.500.12381/5572 | |
| Acceso abierto | |
| Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND) |
| _version_ | 1881639880391393280 |
|---|---|
| author | Chiesa, Camila |
| author2 | Perez-Torrado, Valentina Mezzano, Rossana Vazquez, Carolina Criscuolo, Zelika Serra, Marcelo Marambaud, Philippe Escande, Carlos Ruiz, Santiago |
| author2_role | author author author author author author author author |
| author_facet | Chiesa, Camila Perez-Torrado, Valentina Mezzano, Rossana Vazquez, Carolina Criscuolo, Zelika Serra, Marcelo Marambaud, Philippe Escande, Carlos Ruiz, Santiago |
| author_role | author |
| bitstream.checksum.fl_str_mv | 710ccfef5cb01d54b75d1d847d6b6b7b a35f8fdbe7364cb667d79d24a1efd010 |
| bitstream.checksumAlgorithm.fl_str_mv | MD5 MD5 |
| bitstream.url.fl_str_mv | https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/2/license.txt https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/1/Abstract%2016th%20HHT%20Scientific%20conference.pdf |
| collection | IPMON en REDI |
| dc.creator.none.fl_str_mv | Chiesa, Camila Perez-Torrado, Valentina Mezzano, Rossana Vazquez, Carolina Criscuolo, Zelika Serra, Marcelo Marambaud, Philippe Escande, Carlos Ruiz, Santiago |
| dc.date.accessioned.none.fl_str_mv | 2026-06-08T15:56:42Z |
| dc.date.available.none.fl_str_mv | 2026-06-08T15:56:42Z |
| dc.date.issued.none.fl_str_mv | 2026-06-03 |
| dc.description.abstract.none.fl_txt_mv | Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT. |
| dc.description.sponsorship.none.fl_txt_mv | Agencia Nacional de Investigación e Innovación Brain vascular malformation Consorsium National Institute of Health |
| dc.identifier.anii.es.fl_str_mv | FMV_1_2021_1_166595 |
| dc.identifier.uri.none.fl_str_mv | https://hdl.handle.net/20.500.12381/5572 |
| dc.language.iso.none.fl_str_mv | eng |
| dc.rights.*.fl_str_mv | Acceso abierto |
| dc.rights.license.none.fl_str_mv | Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND) |
| dc.rights.none.fl_str_mv | info:eu-repo/semantics/openAccess |
| dc.source.es.fl_str_mv | HHT International Scientific Conference |
| dc.source.none.fl_str_mv | reponame:IPMON en REDI instname:Institut Pasteur de Montevideo instacron:Institut Pasteur de Montevideo |
| dc.subject.anii.none.fl_str_mv | Ciencias Médicas y de la Salud Medicina Clínica Sistemas Cardíaco y Cardiovascular |
| dc.subject.es.fl_str_mv | vascular pathology BMP9-ALK1-SMAD signaling endothelial cell Hereditary Hemorrhagic Telangiectasia arteriovenous malformation |
| dc.title.none.fl_str_mv | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| dc.type.es.fl_str_mv | Documento de conferencia |
| dc.type.none.fl_str_mv | info:eu-repo/semantics/conferenceObject |
| dc.type.version.es.fl_str_mv | Enviado |
| dc.type.version.none.fl_str_mv | info:eu-repo/semantics/submittedVersion |
| description | Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT. |
| eu_rights_str_mv | openAccess |
| format | conferenceObject |
| id | IPMON_7de68462197745e71d6c6dd0833dca65 |
| identifier_str_mv | FMV_1_2021_1_166595 |
| instacron_str | Institut Pasteur de Montevideo |
| institution | Institut Pasteur de Montevideo |
| instname_str | Institut Pasteur de Montevideo |
| language | eng |
| network_acronym_str | IPMON |
| network_name_str | IPMON en REDI |
| oai_identifier_str | oai:redi.anii.org.uy:20.500.12381/5572 |
| publishDate | 2026 |
| reponame_str | IPMON en REDI |
| repository.mail.fl_str_mv | msarroca@pasteur.edu.uy |
| repository.name.fl_str_mv | IPMON en REDI - Institut Pasteur de Montevideo |
| repository_id_str | 9421_2 |
| rights_invalid_str_mv | Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND) Acceso abierto |
| spelling | Reconocimiento-NoComercial-SinObraDerivada 4.0 Internacional. (CC BY-NC-ND)Acceso abiertoinfo:eu-repo/semantics/openAccess2026-06-08T15:56:42Z2026-06-08T15:56:42Z2026-06-03https://hdl.handle.net/20.500.12381/5572FMV_1_2021_1_166595Objective HHT is caused by loss-of-function mutations in BMP9-ALK1-SMAD signaling in endothelial cells (ECs) and leads to arteriovenous malformations (AVMs). Using a drug repurposing approach, we sought to identify SMAD1/5/8 activators in ECs capable of ameliorating HHT pathology. Here, we identified nitazoxanide and investigated its therapeutic potential. Methods Cell lines and human ECs were treated with nitazoxanide. SMAD1/5/8 activation, ID1 expression and mTOR signaling were assessed by Western blot, immunofluorescence, and flow cytometry. Mechanistic studies included pharmacological inhibition and siRNA-mediated silencing. In vivo efficacy was evaluated in BMP9/10-immunoblocked neonatal mice by analyzing retinal vascular abnormalities and pathway modulation. Results Nitazoxanide induced a robust, dose-dependent increase in SMAD1/5/8 phosphorylation and ID1 expression, with maximal effects at 1 μM, without affecting cell viability. This effect was ALK1-dependent, as pharmacological inhibition or genetic silencing of ALK1 abolished pathway activation, whereas ALK2 silencing had no effect. Under pro-angiogenic conditions, nitazoxanide sustained SMAD1/5/8 activation and inhibited mTOR signaling, as indicated by reduced S6 phosphorylation. In vivo, nitazoxanide significantly reduced AVM number and size, venous dilation, and hypervascularization in the retina. These effects were associated with restoration of SMAD1/5/8 signaling in the lung and normalization of mTOR activity in the liver. Importantly, nitazoxanide restored SMAD signaling in BOECs derived from HHT patients carrying ALK1 or SMAD4 mutations. Conclusion Nitazoxanide prevents HHT vascular pathology in vivo by activating SMAD1/5/8 signaling and inhibiting mTOR. These findings support its potential as a therapeutic strategy for HHT.Agencia Nacional de Investigación e InnovaciónBrain vascular malformation ConsorsiumNational Institute of HealthengHHT International Scientific Conferencereponame:IPMON en REDIinstname:Institut Pasteur de Montevideoinstacron:Institut Pasteur de Montevideovascular pathologyBMP9-ALK1-SMAD signalingendothelial cellHereditary Hemorrhagic Telangiectasiaarteriovenous malformationCiencias Médicas y de la SaludMedicina ClínicaSistemas Cardíaco y CardiovascularNitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology.Documento de conferenciaEnviadoinfo:eu-repo/semantics/submittedVersioninfo:eu-repo/semantics/conferenceObjectInstitut Pasteur de Montevideo//Ciencias Médicas y de la Salud/Medicina Clínica/Sistemas Cardíaco y CardiovascularChiesa, CamilaPerez-Torrado, ValentinaMezzano, RossanaVazquez, CarolinaCriscuolo, ZelikaSerra, MarceloMarambaud, PhilippeEscande, CarlosRuiz, SantiagoLICENSElicense.txtlicense.txttext/plain; charset=utf-85124https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/2/license.txt710ccfef5cb01d54b75d1d847d6b6b7bMD52ORIGINALAbstract 16th HHT Scientific conference.pdfAbstract 16th HHT Scientific conference.pdfChiesa et alapplication/pdf28837https://redi.anii.org.uy/jspui/bitstream/20.500.12381/5572/1/Abstract%2016th%20HHT%20Scientific%20conference.pdfa35f8fdbe7364cb667d79d24a1efd010MD5120.500.12381/55722026-06-08 12:56:43.842oai:redi.anii.org.uy:20.500.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://hdl.handle.net/20.500.12381/575Organismo científico-tecnológicohttps://pasteur.uy/https://redi.anii.org.uy/oai/requestmsarroca@pasteur.edu.uyUruguayopendoar:9421_22026-06-08T15:56:43IPMON en REDI - Institut Pasteur de Montevideofalse |
| spellingShingle | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. Chiesa, Camila vascular pathology BMP9-ALK1-SMAD signaling endothelial cell Hereditary Hemorrhagic Telangiectasia arteriovenous malformation Ciencias Médicas y de la Salud Medicina Clínica Sistemas Cardíaco y Cardiovascular |
| status_str | submittedVersion |
| title | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| title_full | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| title_fullStr | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| title_full_unstemmed | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| title_short | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| title_sort | Nitazoxanide activates BMP9-ALK1-SMAD signaling cascade and improves HHT vascular pathology. |
| topic | vascular pathology BMP9-ALK1-SMAD signaling endothelial cell Hereditary Hemorrhagic Telangiectasia arteriovenous malformation Ciencias Médicas y de la Salud Medicina Clínica Sistemas Cardíaco y Cardiovascular |
| url | https://hdl.handle.net/20.500.12381/5572 |